title: Biologic markers determine both the risk and the timing of recurrence in breast cancer.
abstract: Breast cancer has a long natural history. Established and emerging biologic markers address overall risk but not necessarily timing of recurrence. 346 adjuvant naïve breast cancer cases from Guy's Hospital with 23 years minimum follow-up and archival blocks were recut and reassessed for hormone-receptors (HR), HER2-receptor and grade. Disease-specific survival (DSS) was analyzed by recursive partitioning. To validate insights from this analysis, gene-signatures (proliferative and HR-negative) were evaluated for their ability to predict early versus late metastatic risk in 683 node-negative, adjuvant naïve breast cancers annotated with expression microarray data. Risk partitioning showed that adjuvant naïve node-negative outcome risk was primarily partitioned by tumor receptor status and grade but not tumor size. HR-positive and HER2-negative (HRpos) risk was partitioned by tumor grade; low grade cases have very low early risk but a 20% fall-off in DSS 10 or more years after diagnosis. Higher grade HRpos cases have risk over >20 years. Triple-negative (Tneg) and HER2-positive (HER2pos) cases DSS events occurred primarily within the first 5 years. Among node-positive cases, only low grade conferred late risk, suggesting that proliferative gene signatures that identify proliferation would be important for predicting early but not late recurrence. Using pooled data from four publicly available data sets for node-negative tumors annotated with gene expression and outcome data, we evaluated four prognostic gene signatures: two proliferation-based and two immune function-based. Tumor proliferative capacity predicted early but not late metastatic risk for HRpos cases. The immune function or HRneg specific signatures predicted only early metastatic risk in Tneg and HER2pos cases. Breast cancer prognostic signatures need to inform both risk and timing of metastatic events and may best be applied within subsets. Current signatures predict for outcome risk within 5 years of diagnosis. Predictors of late risk for HR positive disease are needed.
authors: Department of Surgery and Radiology, University of California, San Francisco, CA 94115, USA. laura.esserman@ucsfmedctr.org
authors: Laura J
authors: LJ
authors: Esserman
authors: Dan H
authors: DH
authors: Moore
authors: Pamela J
authors: PJ
authors: Tsing
authors: Philip W
authors: PW
authors: Chu
authors: Christina
authors: C
authors: Yau
authors: Elissa
authors: E
authors: Ozanne
authors: Robert E
authors: RE
authors: Chung
authors: Vickram J
authors: VJ
authors: Tandon
authors: John W
authors: JW
authors: Park
authors: Frederick L
authors: FL
authors: Baehner
authors: Stig
authors: S
authors: Kreps
authors: Andrew N J
authors: AN
authors: Tutt
authors: Cheryl E
authors: CE
authors: Gillett
authors: Christopher C
authors: CC
authors: Benz
references: J Clin Oncol. 1999 May;17(5):1474-81
references: 10334533
references: N Engl J Med. 2004 Dec 30;351(27):2817-26
references: 15591335
references: Clin Cancer Res. 2008 Aug 15;14(16):5158-65
references: 18698033
references: Breast Cancer Res Treat. 2007;105 Suppl 1:45-53
references: 17912635
references: Breast Cancer Res. 2008;10(4):R73
references: 18755024
references: BMC Cancer. 2008 Nov 21;8:339
references: 19025599
references: N Engl J Med. 2003 Nov 6;349(19):1793-802
references: 14551341
references: Breast Cancer Res. 2009;11 Suppl 3:S11
references: 20030862
references: Cancer Control. 2005 Apr;12(2):73-81
references: 15855890
references: Clin Cancer Res. 2007 Jun 1;13(11):3207-14
references: 17545524
references: N Engl J Med. 2011 Jan 20;364(3):205-14
references: 21208101
references: Breast Cancer Res. 2010;12(5):R85
references: 20946665
references: J Natl Cancer Inst. 2006 Feb 15;98(4):262-72
references: 16478745
references: Proc Natl Acad Sci U S A. 2005 Sep 20;102(38):13550-5
references: 16141321
references: Proc Natl Acad Sci U S A. 2005 Mar 8;102(10):3738-43
references: 15701700
references: Nature. 2005 Jul 28;436(7050):518-24
references: 16049480
references: Br J Cancer. 1996 Jun;73(12):1545-51
references: 8664127
references: J Clin Oncol. 2005 Apr 20;23(12):2716-25
references: 15837986
references: Health Expect. 2001 Mar;4(1):48-57
references: 11286599
references: Nature. 2002 Jan 31;415(6871):530-6
references: 11823860
references: Lancet. 2005 May 14-20;365(9472):1687-717
references: 15894097
references: Med J Aust. 1999 Sep 20;171(6):290-4
references: 10560442
references: Nature. 2000 Aug 17;406(6797):747-52
references: 10963602
references: Breast Cancer Res. 2010;12(5):R68
references: 20813035
references: Lancet. 2005 Feb 19-25;365(9460):671-9
references: 15721472
references: Breast Cancer Res. 2008;10(4):R65
references: 18662380
references: Breast Cancer Res. 2008;10(6):R93
references: 19014521
references: Pol J Pathol. 2004;55(4):165-71
references: 15757204
references: Proc Natl Acad Sci U S A. 2001 Sep 11;98(19):10869-74
references: 11553815
references: Histopathology. 1991 Nov;19(5):403-10
references: 1757079
references: Arch Pathol Lab Med. 2007;131(1):18-43
references: 19548375
references: Oncologist. 2008 May;13(5):477-93
references: 18515733
references: J Natl Cancer Inst. 2006 Sep 6;98(17):1183-92
references: 16954471
references: Clin Cancer Res. 2008 Mar 1;14(5):1368-76
references: 18316557
references: J Clin Oncol. 1996 Oct;14(10):2738-46
references: 8874335
references: BMC Genomics. 2006 Apr 27;7:96
references: 16643655
references: Stat Med. 2007 Mar 15;26(6):1360-7
references: 16900575